Polyphor's Stock Slides As Murepavadin Trials Are Halted

 
• By Kevin Grogan

The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.

Stock market
Polyphor stock stumbles in Switzerland • Source: Shutterstock

More from Anti-infective

More from Therapy Areas